BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Indiana University - Ohio State University Center Gets $9 Million More For Cancer Epigenetics From National Cancer Institute


6/10/2010 11:53:25 AM

BLOOMINGTON, Ind. -- Indiana University and the Ohio State University will receive $9 million from the National Cancer Institute to continue studying cancer genes and the sometimes-unnatural agents that mask the genes' expression, a phenomenon called epigenetics.

The National Cancer Institute is a division of the National Institutes of Health.

OSU School of Medicine cancer geneticist Timothy Huang and IU School of Medicine cancer biologist Kenneth Nephew co-administer the OSU-IU Center for Cancer Systems Biology and its project, "Interrogating Epigenetic Changes in Cancer Genomes," which began in 2004 with about $8 million in NCI support. Ten other centers received funding or continued funding this year as part of the NCI's Integrative Cancer Biology Program.

"Our group uses integrated computational and experimental approaches to study epigenetic mechanisms that control signaling networks in prostate, breast, and ovarian cancers," said Nephew, a member of the IU School of Medicine's Bloomington faculty. "During the initial funding period, we focused on epigenetic processes associated with neoplastic transformation of normal cells into cancer cells. We demonstrated that disruption of key networks contribute to the development of breast, prostate, and ovarian cancer, and we developed mathematical models based on our experimental data."

Over the next five years, Nephew said the OSU/IU-led team will study epigenetic changes in prostate, breast, and ovarian cancer cells that cause resistance to hormonal therapy or traditional chemotherapy. Nephew said a major objective is to identify a panel of epigenetic biomarkers for predicting responsiveness to anti-hormone treatments and chemotherapies in cancer patients.

"These centers represent a unique multidisciplinary union of outstanding scientists and clinicians who will work to unravel the complexities of cancer through the novel application of technology and mathematical modeling," said Dan Gallahan, NCI Integrative Cancer Biology Program director. "Their discoveries and models will be critical to our continued success in understanding and treating this disease."

The OSU-IU center also has an "Education Core," which is training young scientists to conduct integrated cancer research. During the initial funding period, the OSU-IU center hosted 14 summer programs and co-organized two systems biology meetings. Center staff trained 137 undergraduate, graduate, and post-graduate students and supported the activities of more than a dozen short- and long-term visitors.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES